Physician profile
Robert Rees Durant
NPI 1932399292
$11,830.76
in general payments reported to CMS, 2019-2025
30 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $1,053 · 2021: $1,433 · 2022: $2,220 · 2023: $2,037 · 2024: $2,210 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,193 · Education: $3.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,192.70 |
| Education | $3.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,257.95 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,092.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $1,013.99 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $1,001.15 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $910.78 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $841.57 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $707.28 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $641.76 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Janssen Pharmaceuticals, INC | $582.43 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $566.61 | 2019-2022 | |
| Lundbeck LLC | $527.42 | 2019-2025 | Rexulti |
| Tris Pharma INC | $469.83 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $293.62 | 2023-2025 | Caplyta |
| Almatica Pharma LLC | $279.72 | 2024-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $226.93 | 2024-2025 | Xelstrym |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $200.20 | 2019-2020 | |
| Adlon Therapeutics L.P. | $164.28 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $151.55 | 2019-2023 | Xywav |
| Teva Pharmaceuticals USA, INC. | $126.75 | 2024-2025 | Uzedy |
| Alkermes, INC. | $110.96 | 2021-2023 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $110.24 | 2023-2024 | Quviviq |
| Harmony Biosciences LLC | $105.15 | 2022-2023 | Wakix |
| Bausch Health US, LLC | $86.97 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $86.37 | 2022-2024 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $86.28 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $78.85 | 2019 | |
| Collegium Pharmaceutical, INC. | $52.98 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $25.59 | 2019 | |
| Pfizer INC. | $17.79 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Durant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.